VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Exciting results from CARTITUDE-1: anti-BCMA CAR-T for MM

JNJ-4528 is CAR T-cell therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity. Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses the results from the CARTITUDE-1 trial (NCT03548207), a phase Ib/II study of JNJ-4528 in patients with relapsed and/or refractory multiple myeloma (MM). Dr Berdeja highlights the very exciting results, including measurable residual disease (MRD) negativity in all evaluable patients tested and a manageable safety profile. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter